Compare BUDA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUDA | CGTX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | 39 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.7M | 102.9M |
| IPO Year | N/A | 2021 |
| Metric | BUDA | CGTX |
|---|---|---|
| Price | $7.78 | $0.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $14.00 | $3.33 |
| AVG Volume (30 Days) | 21.5K | ★ 1.1M |
| Earning Date | 03-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.25 | $0.55 |
| 52 Week High | $12.00 | $3.83 |
| Indicator | BUDA | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 37.08 |
| Support Level | $8.05 | $0.55 |
| Resistance Level | $10.42 | $1.19 |
| Average True Range (ATR) | 0.64 | 0.06 |
| MACD | -0.21 | -0.00 |
| Stochastic Oscillator | 25.71 | 7.27 |
Buda Juice Inc operates in a beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never heat-treated, pasteurized, never HPP- processed, never UV- treated and always cold.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).